Skip to main content
SpringerLink
Log in

A proposal for future Helicobacter pylori eradication guidelines

  • Chapter
Helicobactor pylori

  • 159 Accesses

Abstract

The worldwide economic burden resulting from Helicobacter pylori-related direct and indirect diseases is enormous. H. pylori eradication strategies mainly target dyspeptic populations and recommend non-invasive testing and eradication for all such patients without alarm symptoms at their first presentation, with certain age limits depending on local gastric cancer incidence. The precise role of H. pylori infection in non-ulcer dyspepsia, users of non-steroidal anti-inflammatory drugs (NSAIDs) and in patients with gastro-oesophageal reflux disease (GORD) remain unknown, while guidelines generally favour eradication. The efficacy and cost-effectiveness of the ‘test-and-treat’ approach are well established. There is emerging strong evidence linking H. pylori infection to gastric cancer. We propose a global ‘search-and-treat’ paradigm for future H. pylori eradication guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Axon ATR. Acute infection with H. pylori. In: Hunt RH, Tytgat GN, editors. Helicobacter pylori: Basic Mechanism to Clinical Cure. Lancaster: Kluwer, 1994: 407–12.

    Google Scholar 

  2. Vaira D, Miglioli M, Mule P et al. Prevalence of peptic ulcer in H. pylori positive blood donors. Gut. 1994; 35: 309–12.

    Article  PubMed  CAS  Google Scholar 

  3. Malfertheiner P, Megraud F, O’Morain C et al. Current concept in the management of Helicobacter pylori infection–the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167–80.

    Article  PubMed  CAS  Google Scholar 

  4. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med J. 1989; 289: 30–2.

    Article  Google Scholar 

  5. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol. 1991; 26 (Suppl. 182): 17–24.

    Article  Google Scholar 

  6. Buckley M, O’Morain CA. Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther. 1995; 9 (Suppl.): 53–8.

    PubMed  Google Scholar 

  7. Rosenstoch S, Kay L, Rosenstock C et al. Relation between H. pylori infection and gastrointestinal symptoms and syndromes. Gut. 1997; 41: 169–76.

    Article  Google Scholar 

  8. Parsonnet J, Blaser MJ, Perez-Perez I et al. Symptoms and risk factors of Helicobacter infection in a cohort of epidemiologists. Gastroenterology. 1992; 102: 41–6.

    PubMed  CAS  Google Scholar 

  9. European Helicobacter pylori Study Group. Current European concept in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut. 1997; 41: 8–14.

    Google Scholar 

  10. American Gastroenterological Association. American Gastroenterological Association medical position statement. Evaluation of dyspepsia. Gastroenterology. 1998; 114: 549–58.

    Google Scholar 

  11. Hunt RH, Thompson ABR. Canadian Helicobacter consensus conference. Can J Gastroenterol. 1998; 12: 31–41.

    PubMed  CAS  Google Scholar 

  12. Moayyedi P, Soo S, Deeks J et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J. 2000; 321: 659.

    Article  CAS  Google Scholar 

  13. Talley NJ, Janssens J, Lauritsen K et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 month’s follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J. 1999; 318: 833–7.

    Article  CAS  Google Scholar 

  14. McColl K, Murray L, El-Omer et al. Symptomatic benefit from eradicating H. pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998; 339: 1869–74.

    Article  PubMed  CAS  Google Scholar 

  15. Kostenpato J, Farkkila M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol. 2001; 96: 2866–72.

    Article  Google Scholar 

  16. Chiba N, Vedhuyzen van Zanten SJO, Sinclair P et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. Br Med J. 2002; 324: 1012.

    Google Scholar 

  17. Blum AL, Talley NJ, O’Morain C et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998; 339: 1875–81.

    Article  PubMed  CAS  Google Scholar 

  18. Talley NJ, Vakil N, Ballard ED 2nd et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Eng J Med. 1999; 341: 1106–11.

    Article  CAS  Google Scholar 

  19. Talley NJ, Meineche-Schmidt P, Duckworth P et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomised, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998; 12: 1055–65.

    Article  PubMed  CAS  Google Scholar 

  20. Fallone CA, Barkun AN, Friedman G et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000; 95: 914–20.

    Article  PubMed  CAS  Google Scholar 

  21. McColl KEL, Dickson A, El-Nujmi A et al. Symptomatic benefit 1–3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol. 2000; 95: 101–5.

    PubMed  CAS  Google Scholar 

  22. Malfertheiner P, Veldhuyzen van Z, Dent J. Does cure of Helicobacter pylori infection induce heartburn? Gastroenterology. 1998; 114: A212 (abstract).

    Article  Google Scholar 

  23. Malfertheiner P, Dent J, Zeijlon L et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease–results from a randomised trial programme. Aliment Pharmacol Ther. 2002; 16: 1431–42.

    Article  PubMed  CAS  Google Scholar 

  24. O’Connor HJ, O’Morain CA. Helicobacter pylori and gastroesophageal reflux disease: to treat or not to treat? Scand J Gastroenterol. 2001; 7: 677–82.

    Article  Google Scholar 

  25. Huang J-Q, Sridhar A, Hunt RH. Role of H. pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002; 359: 14–22.

    Article  PubMed  CAS  Google Scholar 

  26. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of H. pylori eradication in patients on non-steroidal anti-inflammatory drugs. HELP NSAID Study. Lancet. 1998; 352: 1016–21.

    Article  PubMed  CAS  Google Scholar 

  27. Chan FKL, Sung JJY, Suen R et al. Does eradication of H. pylori impair healing of non-steroidal anti-inflammatory drug associated bleeding peptic ulcer? A prospective randomised study. Aliment Pharmacol Ther. 1998; 12: 1201–5.

    Article  PubMed  CAS  Google Scholar 

  28. Chan FKL, To KF, Wu JCY et al. Eradication of H. pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002; 359: 9–13.

    Article  PubMed  CAS  Google Scholar 

  29. Chan FK, Chung Sc, Suen Bym Lee YT et al. Preventing recurrent upper gastrointestinal bleeding in patients with H. pylori infection who are taking low-dose aspirin or naproxen. New Engl J Med. 2001; 344: 967–73.

    Article  PubMed  CAS  Google Scholar 

  30. Lanas A, Fuentes J, Benito R et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Phamacol Ther. 2002; 16: 779–86.

    Article  CAS  Google Scholar 

  31. Veldhuyzen van Zanten SJO, Bradette M, Farley A et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther. 1999; 13: 289–95.

    Article  PubMed  CAS  Google Scholar 

  32. Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther. 1999; 13: 703–12.

    Article  PubMed  CAS  Google Scholar 

  33. Damman HG, Folsch UR, Hahn EG et al. Eradication of H. pylori with pantoprazole, clarithromycin, and metrinidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter. 2000; 5: 41–51.

    Article  Google Scholar 

  34. Pilotto A, Leandro G, Franceschi M et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther. 1999; 13: 667–73.

    Article  PubMed  CAS  Google Scholar 

  35. Pilotto A, Franceschi M, Leandro G et al. Efficacy of 7-day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol. 1999; 14: 468–75.

    Article  PubMed  CAS  Google Scholar 

  36. Miwa H, Yamada T, Sato K et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci. 2000; 45: 77–82.

    Article  PubMed  CAS  Google Scholar 

  37. Lee JM, Deasy F, O’Morain CA. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol. 2000; 12: 433–7.

    Article  PubMed  CAS  Google Scholar 

  38. Labenz J, Malfertheiner P. [Helicobacter pylori - when and how do gastroenterologists treat themselves? A clinical and practical survey]. Dtsch Med Wochenschr. 1997; 133: 637–42.

    Google Scholar 

  39. Fallone CA, Loo V, Joseph L et al. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer resurgence: a randomised controlled trial. Clin Invest Med. 1999; 22: 185–94.

    PubMed  CAS  Google Scholar 

  40. Geogopoulos SD, Ladas SD, Karatapanis S et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprozole, amoxicillin and clarithromycin. Dig Dis Sci. 2000; 45: 63–67.

    Article  Google Scholar 

  41. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci. 2000; 45: 265–71.

    Article  PubMed  CAS  Google Scholar 

  42. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999; 159: 2312–16.

    Article  PubMed  CAS  Google Scholar 

  43. Ellenrieder V, Boeck W, Richter C et al. Prevalence of resistance to clarithromycin and its clinical importance on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol. 1999; 34: 750–6.

    Article  PubMed  CAS  Google Scholar 

  44. Avidan B, Melzer E, Keller N, Bar-Meir S. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J. 2001; 3: 163–5.

    PubMed  CAS  Google Scholar 

  45. Murakami K, Satoh R, Okimoto T, Kagawa J, Fujioka T, Kodama M. [Selection of antibiotics and planning of eradication for H. pylori infection]. Nippon Rinsho. 2001; 59: 308–13.

    Google Scholar 

  46. Sakurai K, Takahashi H, Yamaguchi Y et al. [Importance of drug selection and the use of sensitivity tests in the eradication therapy for Helicobacter pylori]. Nippon Rinsho. 1999;57:72–5.

    Google Scholar 

  47. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs. 1999; 57: 905–20.

    Article  PubMed  CAS  Google Scholar 

  48. Xiao SD, Liu WZ, Hu PJ et al. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment Pharmacol Ther. 2001; 15: 81–6.

    Article  PubMed  CAS  Google Scholar 

  49. Huang AH, Sheu BS, Yang HB et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprozole-based triple therapy. J Formos Med Assoc. 2000; 99: 704–9.

    PubMed  CAS  Google Scholar 

  50. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol. 2002; 31: 128–39.

    Article  PubMed  Google Scholar 

  51. Spliller RC. Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Eur J Gastroenterol Hepatol. 1999;11(Suppl. 2): discussion 54305.

    Google Scholar 

  52. Pilotto A, Franceschi M, Di Mario F. Helicobacter pylori-associated peptic ulcer disease in elderly patients. Clin Geriatr. 2000; 8: 49–58.

    Google Scholar 

  53. Asaka M, Kato M, Kudo M et al. Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than ageing: studies in asymptomatic Japanese adults. Helicobacter. 1996; 1: 52–6.

    Article  PubMed  CAS  Google Scholar 

  54. DeLuca VA, West AB, Hague S et al. Long-term symptom patterns, endoscopie findings, and gastric histology in Helicobacter pylori-infected and uninfected patients. J Clin Gastroenterol. 1998; 26: 106–12.

    Article  PubMed  Google Scholar 

  55. Sanduleanu S, Jonkers D, De Bruïne A et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001; 15: 1163–75.

    Article  PubMed  CAS  Google Scholar 

  56. Moayyedi P, Morrow S, Peacock R et al. Changing patterns of H. pylori gastritis in longstanding acid suppression. Gut. 1999; 44 (Suppl. 1): A117.

    Google Scholar 

  57. Kuipers EJ, Uyterlinde AM, Pena AS et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995; 90: 1401–6.

    PubMed  CAS  Google Scholar 

  58. El-Nujumi A, Williams C, Ardill JE et al. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut. 1998; 42: 159–65.

    Article  PubMed  CAS  Google Scholar 

  59. Solcia E, Fiocca R, Villani L et al. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Scand J Gastroenterol. 1996; 31 (Suppl. 215): 105–10.

    Article  CAS  Google Scholar 

  60. Tahara E. Molecular biology of gastric cancer. World J Surg. 1995; 19: 484–8.

    Article  PubMed  CAS  Google Scholar 

  61. Rokkas T, Filepe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991; 32: 1110–13.

    Article  PubMed  CAS  Google Scholar 

  62. de Boer WA, Tytgat GN. Search and treat strategy to eliminate Helicobacter pylori associated ulcer disease. Gut. 2001: 48: 567–70.

    Article  PubMed  Google Scholar 

  63. Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol. 2002; 55: 770–3.

    Article  PubMed  CAS  Google Scholar 

  64. El-Omer EM, Oien K, Murray LS et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000; 118: 22–30.

    Article  Google Scholar 

  65. Yu I, Leung WK, Go MY et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut. 2002; 51: 480–4.

    Article  PubMed  CAS  Google Scholar 

  66. Kokkola A, Sipponen P, Rautelin H et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther. 2002; 16: 515–20.

    Article  PubMed  CAS  Google Scholar 

  67. Vakil N, Rhew D, Soll A, Ofman JJ. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol. 2000; 95: 1691–8.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Qasm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. O’Morain
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, L8N 3Z5, Hamilton, Ontario, Canada

    Richard H. Hunt (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Gastroenterology and Hepatology, Academic Medical Centre, 9 Meibergdreef, 1105 AZ, Amsterdam, The Netherlands

    Guido N. J. Tytgat (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Qasm, A., Buckley, M., O’Connor, H., O’Morain, C. (2003). A proposal for future Helicobacter pylori eradication guidelines. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobactor pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1763-2_55

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-1763-2_55

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-5778-5

  • Online ISBN: 978-94-017-1763-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation